Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Fresenius    FRE   DE0005785604

FRESENIUS

(FRE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Annual General Meeting: Fresenius on course for continued growth, 26th straight increase in dividend approved

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2019 | 09:33am EDT

Fresenius remains on course for growth despite some recent challenges, Stephan Sturm, CEO of Fresenius, told the Annual General Meeting in Frankfurt today. '2018 was not an easy year, and yet it was a successful one,' he said in a speech to shareholders. 'Fresenius is in very good shape. All indications point to continued, profitable growth.'

The basis for this will be increased investments in the current business year, Sturm said. He confirmed the global healthcare group's ambitious targets1 for 2020 to 2023 of organic sales growth averaging 4 to 7 percent annually and an average increase in net income2 of 5 to 9 percent.

'What we do is more important than ever,' Sturm said. 'The healthcare market is growing. People are living longer, and around the world the demand for high-quality medicine is rising. Needs and expectations are also changing: It is no longer about preserving lives, but about raising quality of life for people well into old age. It is also about keeping quality healthcare affordable. These are big challenges! But challenges that we are superbly positioned to meet.'

Shareholders approved with a majority of 90.96 percent the proposal of the General Partner and the Supervisory Board to increase the dividend for the 26th consecutive time. It was raised by 7 percent, to €0.80 per share.

Shareholder majorities of 98.49 percent and 87.53 percent, respectively, approved the actions of the Management and Supervisory Boards in 2018.

At the Annual General Meeting, 72.46 percent of the subscribed capital was represented.

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, and the availability of financing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Disclaimer

Fresenius SE & Co. KGaA published this content on 17 May 2019 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 17 May 2019 13:32:08 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FRESENIUS
06/21FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/14FRESENIUS : Medical Care successfully places USD bonds
PU
06/12FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
06/11FRESENIUS : Kabi Introduces Neostigmine Methylsulfate Injection, USP Simplist Pr..
AQ
06/06Will Europe's clampdown on faulty medical devices hurt patients?
RE
06/03FRESENIUS SE & CO. KGAA : Release according to Article 40, Section 1 of the WpHG..
EQ
05/31FRESENIUS SE & CO. KGAA : Release according to Article 41 of the WpHG [the Germa..
EQ
05/20FRESENIUS : Ex-dividend day for final dividend
FA
05/17ANNUAL GENERAL MEETING : Fresenius on course for continued growth, 26th straight..
PU
05/16FRESENIUS : Medical Care stays on course for growth – Annual General Meeti..
PU
More news
Financials (€)
Sales 2019 35 292 M
EBIT 2019 4 697 M
Net income 2019 1 892 M
Debt 2019 17 501 M
Yield 2019 1,69%
P/E ratio 2019 14,48
P/E ratio 2020 13,41
EV / Sales 2019 1,26x
EV / Sales 2020 1,16x
Capitalization 26 817 M
Chart FRESENIUS
Duration : Period :
Fresenius Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 57,4 €
Spread / Average Target 19%
EPS Revisions
Managers
NameTitle
Stephan Sturm President & Chief Executive Officer
Gerd Krick Chairman-Supervisory Board
Rachel Clare Empey Chief Financial Officer
Niko Stumpfögger Deputy Chairman-Supervisory Board
Klaus-Peter Müller Member-Supervisory Board
Sector and Competitors
1st jan.Capitalization (M$)
FRESENIUS13.71%28 748
AIER EYE HOSPITAL GROUP CO LTD--.--%12 927
BANGKOK DUSIT MEDICAL SERVICES PCL--.--%12 741
IHH HEALTHCARE BHD--.--%11 573
RAMSAY HEALTH CARE LIMITED24.58%9 884
HAPVIDA PARTICIPACOES E INVESTIMENTOS SA26.12%6 362